Cargando…
QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
OBJECTIVES: Reduced neuropsychological outcomes are a major concern in pediatric patients with malignant brain tumors. We aimed to estimate decline in cognitive function according to treatment regimens. METHODS: Cross-sectional analysis of cognitive functions tested with the Neuropsychological Basic...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715612/ http://dx.doi.org/10.1093/neuonc/noaa222.676 |
_version_ | 1783618996374863872 |
---|---|
author | Mynarek, Martin Neumann-Holbeck, Anne Resch, Anika Ottensmeier, Holger von Hoff, Katja Traunwieser, Thomas Kortmann, Rolf-Dieter Obrecht, Denise Warmuth-Metz, Monika Bison, Brigitte Pietsch, Torsten Pfister, Stefan M Sill, Martin Kool, Marcel Sturm, Dominik Jones, David von Deimling, Andreas Sahm, Felix Tischler, Tanja Rutkowski, Stefan |
author_facet | Mynarek, Martin Neumann-Holbeck, Anne Resch, Anika Ottensmeier, Holger von Hoff, Katja Traunwieser, Thomas Kortmann, Rolf-Dieter Obrecht, Denise Warmuth-Metz, Monika Bison, Brigitte Pietsch, Torsten Pfister, Stefan M Sill, Martin Kool, Marcel Sturm, Dominik Jones, David von Deimling, Andreas Sahm, Felix Tischler, Tanja Rutkowski, Stefan |
author_sort | Mynarek, Martin |
collection | PubMed |
description | OBJECTIVES: Reduced neuropsychological outcomes are a major concern in pediatric patients with malignant brain tumors. We aimed to estimate decline in cognitive function according to treatment regimens. METHODS: Cross-sectional analysis of cognitive functions tested with the Neuropsychological Basic Diagnostic tool (NBD) in 279 patients >4 years at diagnosis (median: 8.66; range: 4.01–18.98) with medulloblastoma (n=110, 23.7–25.0Gy CSI; n=131, >30Gy CSI) or posterior fossa ependymoma (n=38 local radiotherapy) who participated in the HIT-2000 trial. Multivariable regression analysis was conducted to adjust for postoperative cerebellar mutism syndrome, preoperative hydrocephalus, postoperative shunt placement, the interval between diagnosis and assessment, sex and age. RESULTS: Mean time from diagnosis to assessment was 5.1 years. Increasing CSI-dose was significantly associated with a deterioration in performance of most subtests, particularly in areas of fluid intelligence (mean z-values per test for no CSI/23.4Gy/>30Gy respectively: matrix reasoning:-0.40/-0.52/-0.98, p<.001), short-term memory (number recall: -0.07/-0.58/-0.64, p=.002), visuo-spatial skills (visual-motor integration:-0.49/-0.68/-1.12, p<.001) and fine motor skills (dominant-hand:-1.09/-1.80/-2.12, p=.008; non-dominant-hand:-1.47/-2.59/-2.82, p=.003; bimanual coordination:-1.33/-2.68/-2.76, p=.001). These differences were retained after adjustment for confounding variables. Within medulloblastoma patients treated with >30Gy CSI, selective attention, but no other function was reduced in patients treated with pre-radiotherapy chemotherapy including intraventricular MTX (selective attention (with chemotherapy/without chemotherapy mean z-values: -0.66/0.00, p=.006)). Patients with SHH-activated medulloblastoma did significantly better than WNT or Group3/Group4 medulloblastoma patients in fluid intelligence and fine motor skills. CONCLUSION: CSI dose among other highly relevant factors had significant effects on neuropsychological outcome. Pre-radiotherapy intraventricular MTX had only minor effects. Patients with SHH-activated medulloblastomas showed a more favorable outcome when compared to patients in the other subgroups. |
format | Online Article Text |
id | pubmed-7715612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77156122020-12-09 QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL Mynarek, Martin Neumann-Holbeck, Anne Resch, Anika Ottensmeier, Holger von Hoff, Katja Traunwieser, Thomas Kortmann, Rolf-Dieter Obrecht, Denise Warmuth-Metz, Monika Bison, Brigitte Pietsch, Torsten Pfister, Stefan M Sill, Martin Kool, Marcel Sturm, Dominik Jones, David von Deimling, Andreas Sahm, Felix Tischler, Tanja Rutkowski, Stefan Neuro Oncol Neuropsychology/Quality of Life OBJECTIVES: Reduced neuropsychological outcomes are a major concern in pediatric patients with malignant brain tumors. We aimed to estimate decline in cognitive function according to treatment regimens. METHODS: Cross-sectional analysis of cognitive functions tested with the Neuropsychological Basic Diagnostic tool (NBD) in 279 patients >4 years at diagnosis (median: 8.66; range: 4.01–18.98) with medulloblastoma (n=110, 23.7–25.0Gy CSI; n=131, >30Gy CSI) or posterior fossa ependymoma (n=38 local radiotherapy) who participated in the HIT-2000 trial. Multivariable regression analysis was conducted to adjust for postoperative cerebellar mutism syndrome, preoperative hydrocephalus, postoperative shunt placement, the interval between diagnosis and assessment, sex and age. RESULTS: Mean time from diagnosis to assessment was 5.1 years. Increasing CSI-dose was significantly associated with a deterioration in performance of most subtests, particularly in areas of fluid intelligence (mean z-values per test for no CSI/23.4Gy/>30Gy respectively: matrix reasoning:-0.40/-0.52/-0.98, p<.001), short-term memory (number recall: -0.07/-0.58/-0.64, p=.002), visuo-spatial skills (visual-motor integration:-0.49/-0.68/-1.12, p<.001) and fine motor skills (dominant-hand:-1.09/-1.80/-2.12, p=.008; non-dominant-hand:-1.47/-2.59/-2.82, p=.003; bimanual coordination:-1.33/-2.68/-2.76, p=.001). These differences were retained after adjustment for confounding variables. Within medulloblastoma patients treated with >30Gy CSI, selective attention, but no other function was reduced in patients treated with pre-radiotherapy chemotherapy including intraventricular MTX (selective attention (with chemotherapy/without chemotherapy mean z-values: -0.66/0.00, p=.006)). Patients with SHH-activated medulloblastoma did significantly better than WNT or Group3/Group4 medulloblastoma patients in fluid intelligence and fine motor skills. CONCLUSION: CSI dose among other highly relevant factors had significant effects on neuropsychological outcome. Pre-radiotherapy intraventricular MTX had only minor effects. Patients with SHH-activated medulloblastomas showed a more favorable outcome when compared to patients in the other subgroups. Oxford University Press 2020-12-04 /pmc/articles/PMC7715612/ http://dx.doi.org/10.1093/neuonc/noaa222.676 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neuropsychology/Quality of Life Mynarek, Martin Neumann-Holbeck, Anne Resch, Anika Ottensmeier, Holger von Hoff, Katja Traunwieser, Thomas Kortmann, Rolf-Dieter Obrecht, Denise Warmuth-Metz, Monika Bison, Brigitte Pietsch, Torsten Pfister, Stefan M Sill, Martin Kool, Marcel Sturm, Dominik Jones, David von Deimling, Andreas Sahm, Felix Tischler, Tanja Rutkowski, Stefan QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL |
title | QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL |
title_full | QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL |
title_fullStr | QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL |
title_full_unstemmed | QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL |
title_short | QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL |
title_sort | qol-13. neurocognitive outcomes according to risk-adapted treatment regimens for children older than 4 with medulloblastoma and posterior fossa ependymoma – results of the hit2000 trial |
topic | Neuropsychology/Quality of Life |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715612/ http://dx.doi.org/10.1093/neuonc/noaa222.676 |
work_keys_str_mv | AT mynarekmartin qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT neumannholbeckanne qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT reschanika qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT ottensmeierholger qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT vonhoffkatja qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT traunwieserthomas qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT kortmannrolfdieter qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT obrechtdenise qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT warmuthmetzmonika qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT bisonbrigitte qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT pietschtorsten qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT pfisterstefanm qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT sillmartin qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT koolmarcel qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT sturmdominik qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT jonesdavid qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT vondeimlingandreas qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT sahmfelix qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT tischlertanja qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial AT rutkowskistefan qol13neurocognitiveoutcomesaccordingtoriskadaptedtreatmentregimensforchildrenolderthan4withmedulloblastomaandposteriorfossaependymomaresultsofthehit2000trial |